Possia
ticagrelor
Table of contents
Overview
The marketing authorisation for Possia has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Possia
|
| Agency product number |
EMEA/H/C/002303
|
| Active substance |
ticagrelor
|
| International non-proprietary name (INN) or common name |
ticagrelor
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
B01AC24
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
AstraZeneca AB
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
03/12/2010
|
| Contact address |
Gärtunavägen
151 85 Södertälje Sweden |
Product information
24/10/2012 Possia - EMEA/H/C/002303 - WS/0292
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).